Nirmatrelvir-ritonavir effectively lowers hospitalization rates and long COVID symptoms in non-hospitalized, high-risk patients with mild to moderate COVID-19.
By Vijay Kumar MalesuReviewed by Lily Ramsey, LLMOct 30 2024 New research highlights the effectiveness of nirmatrelvir-ritonavir in lowering hospitalization rates and long COVID symptoms in non-hospitalized, high-risk COVID-19 patients.
In December 2021, the Food and Drug Administration granted Emergency Use Authorization for nirmatrelvir plus ritonavir for treating mild to moderate COVID-19 in high-risk populations. Ethical approval was granted by the Dubai Scientific Research Ethics Committee, ensuring that all patient records were anonymized and eliminating the need for written consent. The study targeted adults aged 18 and older who tested positive for SARS-CoV-2 with mild to moderate symptoms.
Baseline characteristics of the patients indicated that those in the nirmatrelvir-ritonavir group were significantly older, with a mean age of 54 years, compared to 37 years in the no-treatment group . Gender distribution was similar across both groups, with approximately half of the patients being male .
Covid-19 Ritonavir Cardiovascular Disease Coronavirus Diabetes Efficacy Food Global Health Healthcare Medicine Obesity Omicron Research Respiratory SARS SARS-Cov-2 Severe Acute Respiratory Severe Acute Respiratory Syndrome Syndrome
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Covid hospitalisations among infants remain highUnder 1s account for 64 per cent of all childhood hospital admissions with Covid, study finds
Read more »
Most pregnant people got vaccinated for COVID-19 in 2022, finds Canadian studyA study of more than 28,000 pregnancies from 2022 has found that the majority of pregnant people received the COVID-19 vaccine during its initial release.
Read more »
New warning to anyone who has had Covid in the past three yearsA new study into the long term effects of Covid-19 has been published
Read more »
COVID-induced immune memory could protect against severe cases of flu, mouse study suggestsMore than 200 viruses can infect and cause disease in humans; most of us will be infected by several over the course of a lifetime.
Read more »
New humanized mouse models created to study COVID-19Scientists at La Jolla Institute for Immunology (LJI) have developed six lines of humanized mice that can serve as valuable models for studying human cases of COVID-19.
Read more »
Study reveals widespread long-COVID symptoms, challenging WHO definitionStudy reveals that more than one-third of SARS-CoV-2 positive patients experience long-COVID symptoms three months after an emergency department visit, with significant overlap in symptoms observed among negative patients.
Read more »